Keyphrases
Abciximab
66%
Clotting Time
16%
Cone-and-plate
16%
Eptifibatide
50%
Glycoprotein IIb/IIIa Receptor
16%
GPIIbIIIa
33%
Inhibiting Effect
16%
Kaolin
16%
Mechanism of Action
16%
Microparticles
66%
P-selectin
50%
Patients with Coronary Artery Disease
16%
Platelet Aggregation
16%
Platelet Glycoproteins
16%
Platelet-rich Plasma
33%
Platelets
33%
Procoagulant Activity
100%
Procoagulant Phospholipids
16%
Recalcification
16%
Shear Rate
16%
Shear-induced
33%
Shear-induced Platelet Activation
100%
Surface Translocation
33%
Thrombotic Events
16%
Tirofiban
100%
Viscometer
16%
Medicine and Dentistry
Abciximab
66%
Coronary Artery Disease
16%
Eptifibatide
50%
Microparticle
66%
PADGEM Protein
50%
Phospholipid
16%
Platelet
16%
Platelet Glycoprotein IIb/IIIa
16%
Procoagulant
100%
Receptor
16%
Thrombocyte Activation
100%
Thrombocyte Aggregation
16%
Thrombocyte Membrane
16%
Thrombocyte Rich Plasma
33%
Tirofiban
100%
Volunteer
16%
Pharmacology, Toxicology and Pharmaceutical Science
Abciximab
66%
Clotting Time
16%
Coronary Artery Disease
16%
Eptifibatide
50%
Fibrinogen Receptor
16%
Microparticle
66%
P-Selectin
50%
Phospholipid
16%
Procoagulant
100%
Receptor
16%
Tirofiban
100%
Biochemistry, Genetics and Molecular Biology
Abciximab
66%
Eptifibatide
50%
P-Selectin
50%
Phospholipid
16%
Platelet
16%
Platelet Glycoprotein IIb/IIIa
16%
Platelet-Rich Plasma
33%
Shear Rate
16%
Thrombocyte Activation
100%
Thrombocyte Aggregation
16%
Thrombocyte Membrane
16%
Tirofiban
100%